Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUENASDAQ:CRDFNASDAQ:SOPHNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.99$4.36$3.20▼$28.60$48.87M0.27421,555 shs217,205 shsCRDFCardiff Oncology$3.03+5.2%$2.92$2.01▼$5.64$201.57M1.811.14 million shs1.31 million shsSOPHSOPHiA GENETICS$2.85-1.4%$3.01$2.58▼$6.28$190.06M1.0361,523 shs28,816 shsTNXPTonix Pharmaceuticals$28.93+9.6%$20.15$6.76▼$574.08$211.91M1.63864,781 shs1.51 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio0.00%+0.40%+19.95%+22.30%-74.63%CRDFCardiff Oncology0.00%+7.83%+4.48%-36.21%-12.43%SOPHSOPHiA GENETICS0.00%-3.72%-6.56%-29.98%-39.36%TNXPTonix Pharmaceuticals0.00%+3.32%+68.30%+215.49%-95.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUEbluebird bio2.3738 of 5 stars3.15.00.00.00.01.71.3CRDFCardiff Oncology1.6703 of 5 stars3.50.00.00.04.30.00.6SOPHSOPHiA GENETICS1.7601 of 5 stars3.45.00.00.00.00.00.6TNXPTonix Pharmaceuticals3.293 of 5 stars3.54.00.00.01.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUEbluebird bio 2.25Hold$44.60793.79% UpsideCRDFCardiff Oncology 3.00Buy$12.00296.04% UpsideSOPHSOPHiA GENETICS 2.75Moderate Buy$6.80138.60% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,922.12% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, TNXP, CRDF, and SOPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/6/2025SOPHSOPHiA GENETICSBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.002/28/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $17.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CRDFCardiff Oncology$587K343.40N/AN/A$1.56 per share1.94SOPHSOPHiA GENETICS$67.17M2.83N/AN/AN/A∞TNXPTonix Pharmaceuticals$10.04M21.10N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/ACRDFCardiff Oncology-$41.44M-$0.92N/AN/AN/A-6,238.17%-73.97%-60.40%N/ASOPHSOPHiA GENETICS-$78.98M-$1.00N/AN/AN/A-110.71%-55.06%-38.33%8/5/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$1,963.61N/AN/AN/A-1,197.86%-163.95%-118.88%N/ALatest BLUE, TNXP, CRDF, and SOPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/4/2025Q4 2024SOPHSOPHiA GENETICS-$0.23-$0.23N/A-$0.23$17.71 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUEbluebird bioN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUEbluebird bio0.370.510.33CRDFCardiff OncologyN/A4.744.74SOPHSOPHiA GENETICS0.123.803.59TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUEbluebird bio87.43%CRDFCardiff Oncology16.29%SOPHSOPHiA GENETICS31.59%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipBLUEbluebird bio1.40%CRDFCardiff Oncology7.70%SOPHSOPHiA GENETICS4.88%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCRDFCardiff Oncology2066.53 million47.15 millionOptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableTNXPTonix Pharmaceuticals507.33 million1.87 millionNot OptionableBLUE, TNXP, CRDF, and SOPH HeadlinesRecent News About These CompaniesPoint72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 25 at 4:04 AM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenMay 24 at 11:33 AM | marketbeat.comTonix Pharmaceuticals CEO Seth Lederman Participates in A.G.P. Annual Healthcare Company ShowcaseMay 22 at 7:38 AM | quiverquant.comTonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company ShowcaseMay 22 at 7:00 AM | globenewswire.comTonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress ReactionMay 21, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 18.8% on Insider Buying ActivityMay 18, 2025 | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above 200-Day Moving Average - Here's WhyMay 17, 2025 | marketbeat.comTonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 ResultsMay 16, 2025 | benzinga.comInsider Buying: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Purchases 4,000 Shares of StockMay 16, 2025 | insidertrades.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 5.05%May 15, 2025 | aaii.comTonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More PositiveMay 15, 2025 | msn.comTonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Beats Expectations By $0.39 EPSMay 14, 2025 | marketbeat.comTonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq. ...May 14, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Appoints New General Counsel and EVP of Operations | TNXP Stock NewsMay 14, 2025 | gurufocus.comTonix Pharma Appoints New General Counsel and EVPMay 14, 2025 | tipranks.comTonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of OperationsMay 14, 2025 | globenewswire.comTonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 13, 2025 | finanznachrichten.deTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | ...May 12, 2025 | gurufocus.comTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12, 2025 | gurufocus.comTonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats Estimates, Revenue at $2. ...May 12, 2025 | gurufocus.comTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%BLUE, TNXP, CRDF, and SOPH Company Descriptionsbluebird bio NASDAQ:BLUE$4.99 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.99 0.00 (-0.10%) As of 05/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Cardiff Oncology NASDAQ:CRDF$3.03 +0.15 (+5.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.02 -0.01 (-0.33%) As of 05/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.SOPHiA GENETICS NASDAQ:SOPH$2.85 -0.04 (-1.38%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.97 +0.12 (+4.21%) As of 05/23/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Tonix Pharmaceuticals NASDAQ:TNXP$28.93 +2.53 (+9.58%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$28.99 +0.06 (+0.21%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
